MassDevice

Edwards shares superior long-term outcomes from TAVR studies

Edwards Lifesciences (NYSE: EW) today announced new data demonstrating long-term benefits with its Sapien heart valve system.
Medscape

Late Post-TAVR Bleeding Linked With Significant Mortality Risks: PARTNER Analysis

NEW YORK, NY — Nearly 6% of patients undergoing transcatheter aortic-valve replacement (TAVR) will experience a late major bleeding complication, and these bleeding events are associated with a ...
Medscape

Late Post-TAVR Mortality Mostly Noncardiac in French Registry

BREST, FRANCE — For patients with severe, symptomatic aortic stenosis in a large French registry, mortality 3 years after transcatheter aortic-valve replacement (TAVR) was high at 42%, but most of the ...
TCTMD

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI

The data are largely in line with those seen at 5 years, but the follow-up reassures there’s no concern about valve ...

Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025

Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical ...
Becker's Hospital Review

TAVR Has Lower Mortality Than Traditional Surgery

High-risk surgical patients with severe aortic stenosis who underwent a transcatheter aortic valve replacement experienced higher one-year survival rates than patients who underwent traditional ...
MedPage Today

DAPT After TAVR: Harm Bleeds Into Mortality Territory

WASHINGTON -- Beyond bleeding alone, a regimen of dual antiplatelet therapy (DAPT) after transcatheter aortic valve replacement (TAVR) was associated with excess mortality, based on observational data ...
Tyler Morning Telegraph

Medtronic Evolut™ TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients

GALWAY, Ireland and CHICAGO, March 30, 2025 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut ...
Kaleido Scope

Still and Cardiothoracic Surgery faculty publish findings on outcomes for high-risk patients following TAVR explantations

Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of aortic valve stenosis. With proven safety and efficacy, TAVR has become a standard therapeutic alternative to surgical ...
Healio

Single antiplatelet therapy linked to reduced mortality after TAVR vs. dual

Please provide your email address to receive an email when new articles are posted on . Single antiplatelet therapy was tied to lower 6-month mortality risk vs. dual antiplatelet therapy after ...
EurekAlert!

Single antiplatelet therapy reduced risk of mortality and major bleeding in patients undergoing transcatheter aortic valve replacement by half

Washington, D.C. – MAY 1, 2025 – Findings from the Transfusion Requirements in Transcatheter Aortic Valve Implantation (TRITAVI) registry demonstrate that single antiplatelet therapy (SAPT) after ...